We are live on !
Find out more
Globeflex Capital Portfolio holdings
AUM
$783M
Turnover
28.73%
1-Year Est. Return
81.58%
This Fund
S&P 500
This Quarter Est. Return
+34.81%
1 Year Est. Return
+81.58%
3 Year Est. Return
+185.88%
5 Year Est. Return
+280.02%
10 Year Est. Return
+1,365.88%
AUM
$783M
AUM Growth
+$122M
(+18%)
Cap. Flow
-$22.1M
Cap. Flow % of AUM
Cap. Flow %
-2.82%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
456
New
69
Increased
67
Reduced
73
Closed
62
Avg Time Held
1.9
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ciena
CIEN
|
+$6.96M |
| 2 |
MYR Group
MYRG
|
+$4.57M |
| 3 |
Leonardo DRS
DRS
|
+$4.16M |
| 4 |
Semtech
SMTC
|
+$3.99M |
| 5 |
Everpure Inc
P
|
+$3.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Catalyst Pharmaceutical
CPRX
|
+$11.2M |
| 2 |
Credicorp
BAP
|
+$9.17M |
| 3 |
Nextpower Inc. Common Stock
NXT
|
+$6.93M |
| 4 |
XP
XP
|
+$6.54M |
| 5 |
Sterling Infrastructure
STRL
|
+$5.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.29% |
| 2 | Industrials | 19.78% |
| 3 | Financials | 17.73% |
| 4 | Healthcare | 17.14% |
| 5 | Consumer Discretionary | 7.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
401
BioMarin Pharmaceuticals
BMRN
$10.9B
| – | – |
-8,719
| Closed | -$493K | – |
|
402
Biote Corp
BTMD
$30.4M
| – | – |
-272,400
| Closed | -$368K | – |
|
403
BorgWarner
BWA
$9.8B
| – | – |
-18,098
| Closed | -$982K | – |
|
404
Pathward Financial
CASH
$1.58B
| – | – |
-864
| Closed | -$77.1K | – |
|
405
Coeur Mining
CDE
$15.8B
| – | – |
-13,763
| Closed | -$258K | – |
|
406
Core Molding Technologies
CMT
$185M
| – | – |
-14,664
| Closed | -$328K | – |
|
|
407
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-450,580
| Closed | -$11.2M | – |
|
408
Crawford & Co Class A
CRD.A
$550M
| – | – |
-67,899
| Closed | -$677K | – |
|
409
Castle Biosciences
CSTL
$1B
| – | – |
-3,759
| Closed | -$92.3K | – |
|
410
Cognizant
CTSH
$28.9B
| – | – |
-4,300
| Closed | -$264K | – |
|
411
Fennec Pharmaceuticals
FENC
$344M
| – | – |
-18,343
| Closed | -$113K | – |
|
412
Flowserve
FLS
$10.2B
| – | – |
-44,497
| Closed | -$3.27M | – |
|
413
Global Industrial
GIC
$1.77B
| – | – |
-7,913
| Closed | -$249K | – |
|
414
Gilead Sciences
GILD
$207B
| – | – |
-12,332
| Closed | -$1.72M | – |
|
415
Chiron Real Estate Inc
XRN
$380M
| – | – |
-13,672
| Closed | -$452K | – |
|
416
FerroAtlántica
GSM
$478M
| – | – |
-32,579
| Closed | -$134K | – |
|
417
HCA Healthcare
HCA
$103B
| – | – |
-4,069
| Closed | -$1.93M | – |
|
418
Hackett Group
HCKT
$333M
| – | – |
-76,921
| Closed | -$1M | – |
|
419
Heritage Financial
HFWA
$1.15B
| – | – |
-27,300
| Closed | -$710K | – |
|
420
Hartford Financial Services
HIG
$35.8B
| – | – |
-18,696
| Closed | -$2.53M | – |
|
421
Home BancShares
HOMB
$5.95B
| – | – |
-4,786
| Closed | -$129K | – |
|
422
Heritage Insurance Holdings
HRTG
$984M
| – | – |
-5,914
| Closed | -$155K | – |
|
423
InfuSystem Holdings
INFU
$274M
| – | – |
-79,961
| Closed | -$738K | – |
|
424
Integra Resources
ITRG
$454M
| – | – |
-93,348
| Closed | -$255K | – |
|
425
Itron
ITRI
$4.32B
| – | – |
-45,491
| Closed | -$4.08M | – |
|
Similar funds
QCM
Globeflex Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Globeflex Capital held 456 positions worth $783M, up 18% from $661M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Globeflex Capital's Q2 2026 filing shows 69 new, 67 increased, 73 reduced and 62 closed positions. Its largest new stake was Ciena: 13,648 shares worth $6.7M. The largest sale was Catalyst Pharmaceutical, an estimated $11.2M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 23% a quarter earlier, followed by Industrials and Financials.
- Globeflex Capital's largest Q2 2026 buy was Ciena: 13,648 shares worth $6.7M.
- Globeflex Capital added most to MYR Group in Q2 2026, an estimated $4.57M increase.
- Globeflex Capital's biggest Q2 2026 reduction was Rigel Pharmaceuticals, cutting an estimated $3.24M.
- Globeflex Capital fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $11.2M.
- Globeflex Capital's ten largest holdings make up 18% of its $783M portfolio in Q2 2026.
- Globeflex Capital opened 69 new positions and closed 62 in Q2 2026.
- Globeflex Capital's portfolio value rose 18% quarter-over-quarter to $783M.
Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.